Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GLS | O94925 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344915 | 1.00 | NR1H2 (0.59) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1785894 | 1.00 | NR1H2 (0.59) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31421369 | 0.95 | NR1H2 (0.57) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31421589 | 0.95 | NR1H2 (0.57) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2071987 | 0.95 | NR1H2 (0.57) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL7448268 | 0.93 | NR1H2 (0.52) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL514696 | 0.90 | NR1H2 (0.62) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL515486 | 0.90 | NR1H2 (0.62) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL621267 | 0.90 | NR1H2 (0.62) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16863978 | 0.90 | NR1H2 (0.58) | NR1H2MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | NEUSCO BIOTECH LIMITED (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4294800-B1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3806853-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2026-03-18 | — | — | EP | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20040102482-A1 | Antibacterial Mutilins | Nabriva Therapeutics GmbH (AT) | 2004-05-27 | — | — | US | disclosed |
| EP-1320525-B1 | ANTIBACTERIAL MUTILINS | BIOCHEMIE GMBH (AT) | 2004-04-21 | — | — | EP | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1320525-A1 | ANTIBACTERIAL MUTILINS | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002022580-A1 | ANTIBACTERIALS MUTILINS | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2002-03-21 | — | — | WO | disclosed |
| CN-1044365-C | Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory diseases and psychosis | SANKYO CO (JP) | 1999-07-28 | — | — | CN | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| CN-1076690-A | SULFONAMIDOCARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 1993-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | NR1H2 2728/4885MEN1 34/4885ALDH1A1 3351/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | NR1H2 32/4885MEN1 1898/4885ALDH1A1 1217/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | NR1H2 5/4885MEN1 2120/4885ALDH1A1 2646/4885 |
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | LPAR1, PLA2R1, LPAR2 | NR1H2 57/4885MEN1 4367/4885ALDH1A1 1113/4885 |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | NR1H2 308/4885MEN1 2043/4885ALDH1A1 1002/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | NR1H2 908/4885MEN1 3585/4885ALDH1A1 1393/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | NR1H2 2537/4885MEN1 1936/4885ALDH1A1 3543/4885 |
| US-20040102482-A1 | Antibacterial Mutilins | MRPS27, MRPS18B, MRPS22 | NR1H2 1004/4885MEN1 2686/4885ALDH1A1 1691/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | NR1H2 450/4885MEN1 2352/4885ALDH1A1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.